Charles Schwab
ATNM icon

Charles Schwab’s Actinium Pharmaceuticals ATNM Stock Holding History

Charles Schwab’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-97,604
Closed -$157K – 3500
2025
Q1 		$157K Buy
97,604
+25,511
+35% +$32.4K ﹤0.01% 3285
2024
Q4 		$90.8K Hold
72,093
– – ﹤0.01% 3405
2024
Q3 		$136K Sell
72,093
-11,484
-14% -$45.4K ﹤0.01% 3364
2024
Q2 		$618K Buy
83,577
+7,369
+10% +$60.7K ﹤0.01% 3101
2024
Q1 		$597K Hold
76,208
– – ﹤0.01% 2962
2023
Q4 		$387K Hold
76,208
– – ﹤0.01% 3163
2023
Q3 		$451K Buy
76,208
+4,216
+6% +$28.1K ﹤0.01% 3081
2023
Q2 		$534K Buy
71,992
+59,466
+475% +$506K ﹤0.01% 3019
2023
Q1 		$118K Buy
+12,526
New +$132K ﹤0.01% 3227
2020
Q3 		– Sell
-2,674
Closed -$29K – 3348
2020
Q2 		$29K Hold
2,674
– – ﹤0.01% 3278
2020
Q1 		$16K Hold
2,674
– – ﹤0.01% 3204
2019
Q4 		$18K Hold
2,674
– – ﹤0.01% 3161
2019
Q3 		$19K Hold
2,674
– – ﹤0.01% 3161
2019
Q2 		$20K Hold
2,674
– – ﹤0.01% 3200
2019
Q1 		$39K Buy
+2,674
New +$42.7K ﹤0.01% 3171
2015
Q2 		– Sell
-970
Closed -$72K – 3095
2015
Q1 		$72K Hold
970
– – ﹤0.01% 3051
2014
Q4 		$172K Hold
970
– – ﹤0.01% 3005
2014
Q3 		$195K Hold
970
– – ﹤0.01% 2955
2014
Q2 		$211K Buy
+970
New +$323K ﹤0.01% 2983

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Charles Schwab's ATNM Position: Q2 2025 in Review

Charles Schwab sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 97,604 shares — an estimated $157K sold.

Charles Schwab first reported a position in ATNM in Q2 2014 and held it in 19 quarters. The position peaked at $618K in Q2 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Charles Schwab reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 97,604 Actinium Pharmaceuticals shares in Q2 2025, an estimated $157K.
  • Charles Schwab first reported a position in Actinium Pharmaceuticals in Q2 2014 and held it in 19 quarters.
  • Charles Schwab's Actinium Pharmaceuticals position peaked at $618K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.